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1ABSTRACT
Effect of hypothyroidism on 5-HT1A receptors in the rat brain 
measured by [18F]Mefway PET
Jae-Hoon Lee
Department of Medicine
The Graduate School, Yonsei University
(Directed by Professor Young Hoon Ryu)
This study investigated the effects of hypothyroidism on the brain serotonin (5-HT) 
1A receptor using animal disease models and 4-(trans-[18F]fluoranylmethyl)-N-[2-[4-(2-
methoxyphenyl)piperazin-1-yl]ethyl]-N-pyridin-2-ylcyclohexane-1-carboxamide 
([18F]Mefway) positron emission tomography (PET) imaging.
Five surgically thyroidectomized male Sprague-Dawley rats were assigned to the 
hypothyroidism group, and five sham-operated male Sprague-Dawley rats were assigned 
to the control group. Hypothyroid status was confirmed by thyroid function tests. After 
anesthesia with 2.0% isoflurane in oxygen, fluconazole was infused at a constant rate for 
one hour to prevent defluorination of the radioligand. Then [18F]Mefway of 8.6–11.1 
MBq was administered at a rate of 1 ml/min and dynamic PET scans were performed 
over the course of 120 min. PET data were reconstructed in user-defined time frames 
using a two-dimensional ordered-subset expectation maximization algorithm. 
2All PET data were spatially normalized to T2-weighted magnetic resonance imaging 
templates, and then time-activity curves of the hippocampus, septum, and cerebellum 
were extracted using predefined volume of interest templates. Non-displaceable binding 
values in the hippocampus and septum were calculated using a multilinear reference 
tissue model, with the cerebellum as the reference tissue, and a ligand-specific parametric 
map was constructed. 
Time-activity curves revealed that the hippocampal and septal uptakes in the 
hypothyroidism group were 25–52% higher than those in the control group, and non-
displaceable binding potentials in the same regions of thyroidectomized rat brains were 
about 30% higher than those in controls. 
In conclusion, hypothyroidism increased the density of postsynaptic 5-HT1A
receptors in the hippocampus and septum. Upregulation of postsynaptic 5-HT1A receptors 
may be responsible for the increased radioligand uptake as an early response to the 
reduced synaptic concentration of 5-HT caused by hypothyroidism.
Key words: [18F]Mefway, hypothyroidism, positron emission tomography, serotonin 1A 
receptor, thyroid
3Effect of hypothyroidism on 5-HT1A receptors in the rat brain 
measured by [18F]Mefway PET
Jae-Hoon Lee
Department of Medicine
The Graduate School, Yonsei University
(Directed by Professor Young Hoon Ryu)
I. INTRODUCTION
Clinical researchers have long recognized the link between the thyroid gland and 
depression. Dysfunction of the hypothalamic-pituitary-thyroid axis (HPT axis), as well as 
the hypothalamic-pituitary-adrenal axis, is a known neuroendocrine factor involved in the 
pathogenesis of depression. Many clinical reports have indicated a high incidence of 
psychiatric illness in patients with either hypothyroidism or hyperthyroidism.1-3 The 
apparent relationship between hypothyroidism and depression has led to the widely 
accepted hypothesis that decreased thyroid function predisposes an individual to 
depression, and, conversely, that improved thyroid function favors recovery from the 
depressed state.4
Thyroid dysfunction may be associated with changes in central neurotransmission, 
and disruptions in thyroid activity have been reported to affect a number of 
4neurotransmitters. Several lines of investigation have produced evidence indicating that 
the serotonin (5-HT) system may be involved in the pathophysiology of mood disorders.5-
8 The currently favored hypothesis is that a lack of serotonin in the brain plays a central 
role in the development and aggravation of such disorders.9 Anatomically, the 5-HT 
system projects to many areas in the central nervous system, several of which play a 
major role in controlling a variety of ‘mood-related’ behaviors, including appetite, sleep, 
and attention.5,7 Such co-occurring clinical and neurophysiological findings in depressed 
patients with hypothyroidism have raised the possibility that there may be a link between 
dysfunction of the HPT axis and the 5-HT system. 
Multiple different 5-HT receptors have been identified in the brain, and among the 
various subtypes of 5-HT1 receptor, that designated 5-HT1A is of particular interest due to 
its possible involvement in anxiety and depression,6 as well as in epilepsy, Parkinson’s 
disease, and Alzheimer’s disease.10-14 Therefore, the importance of an in vivo molecular 
imaging agent for 5-HT1A receptors has been increasingly recognized.
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Positron emission tomography (PET) imaging is a non-invasive functional imaging 
modality for in vivo interrogation of 5-HT1A receptors, due to its extraordinarily high 
sensitivity, which allows the detection of interactions between radiopharmaceuticals and 
their protein targets.16 Although many PET radioligands have been developed for imaging 
5-HT1A receptors, there are no routinely applicable radioligands for use in pre-clinical or 
clinical studies. Recently, 4-(trans-[18F]fluoranylmethyl)-N-[2-[4-(2-
methoxyphenyl)piperazin-1-yl]ethyl]-N-pyridin-2-ylcyclohexane-1-carboxamide
([18F]Mefway) has been developed as a promising radioligand, with highly specific 
binding to 5HT1A receptors, an excellent signal-to-noise ratio, and favorable metabolic 
stability.17,18
In the present study, we investigated the effect of hypothyroidism on 5-HT1A
receptors in the rat brain using animal models of disease and [18F]Mefway PET imaging.
51. Thyroid hormones and mood modulation
It is well established that thyroid hormones are essential for both the development 
and maturation of the human brain, affecting such diverse events as neuronal processing 
and integration, glial cell proliferation, myelination, and the synthesis of key enzymes 
required for neurotransmitter synthesis.19,20 Thyroid deficiency during the perinatal period 
results in irreversible brain damage and mental retardation. 
There are several lines of evidence suggesting that thyroid hormones affect mature 
brain function.21 First of all, thyroid hormone receptors are prevalent in the mature brain. 
Nuclear receptors for triiodothyronine (T3), the thyroid hormone with the highest 
biological activity, are widely distributed in the adult rat brain, with higher densities of 
nuclear T3 receptors in phylogenetically younger brain regions—the amygdala and 
hippocampus—and lower densities in the brain stem and cerebellum.22,23 Secondly, 
deiodinase 2 is expressed primarily in the brain and anterior pituitary gland, where it 
metabolizes thyroxine (T4) to the active thyroid hormone form, T3. The activity of 
deiodinase 2 in distinct regions of the brain varies widely, with the highest levels found in 
cortical areas and lesser activity found in the midbrain, pons, hypothalamus, and 
brainstem.24 Finally, thyroid hormones have been detected in relatively high 
concentrations in cortical tissue.25 In contrast to peripheral tissue, where T4 levels usually 
far exceed those of T3, T4 and T3 concentrations are in a similar range in the brain.
Disorders of the thyroid gland are frequently associated with severe mental 
disturbances.5-8 The observed association between the thyroid system and behavior has 
prompted investigations of the effects of thyroid hormones in modulating affective illness, 
and of the role of the HPT axis in the pathophysiology of mood disorders.26 Thyroid 
hormones have a profound influence on behavior and mood, and appear to be capable of 
modulating the phenotypic expression of major affective illness.26,27 Thyroid hormone 
replacement is now widely accepted as an effective treatment option for patients with 
affective disorders.28,29
62. Transient hypothyroidism during preparation for radioactive iodine treatment
In the past decade, the prevalence of thyroid cancer has increased rapidly, 
particularly in Korea,30,31 and the number of patients who have undergone total 
thyroidectomy has increased accordingly. After total thyroidectomy, patients receive 131I 
radioactive iodine treatment either for ablation of the remnant thyroid tissue or for 
treatment of metastatic or recurrent tumor, depending on their clinical status. To 
maximize the effectiveness of this treatment, thyroid-stimulating hormone (TSH) levels 
must be well above the normal range, and withdrawal from thyroid hormone replacement, 
or induction of hypothyroidism, is the most commonly used means of achieving this goal.
Although this induced hypothyroid state is temporary, lasting just a few weeks, it can 
cause symptoms such as tiredness, weight gain, sleepiness, constipation, muscle aches, 
and reduced concentration.32,33 Emotional changes resembling depression are amongst the 
common symptoms associated with this temporary hypothyroidism. Some people only 
experience mild symptoms, whilst others experience severe symptoms, including suicidal 
ideation.
Patients who prepare for radioactive iodine treatment often suffer from depressive 
symptoms after thyroid hormone withdrawal, and it has been hypothesized that a lack of 
serotonin in the brain plays a central role in this phenomenon. However, the exact 
mechanism by which these symptoms occur requires further elucidation, and we 
hypothesized that PET scanning using [18F]Mefway, a radiotracer for the 5-HT1A receptor, 
would be of great value in investigating the effect of thyroidectomy on the central 
serotonin system.
3. The serotonergic system in the central nervous system
Serotonin is found in the gastrointestinal tract, blood, and central nervous system 
(CNS). About 90% of all serotonin is present in the enterochromaffin cells that are 
dispersed among the mucosal cells in the gastrointestinal tract. Here, 5-HT promotes 
7gastrointestinal motility and contraction of isolated strips of intestine. Around 8% of 5-
HT is present in platelets and facilitates platelet aggregation. The remaining 5-HT (2%) is 
found in the CNS, where it regulates various brain functions, such as mood, appetite, 
sleep, and cognition.
As with the noradrenergic and dopaminergic systems, the bulk of CNS serotonergic 
nerve terminals originate in the neuronal cell bodies of the brainstem’s raphe nuclei, and 
project, both rostrally and caudally, to neuroanatomically discrete areas throughout the 
brain, but with extensive innervation of the cerebral cortex and the limbic system, where 
have been implicated in the pathogenesis of the disorders and thyroid hormone receptors 
are abundant.34 Although the serotonin system has been given prominence in recent 
deliberations about mood modulation, particularly since the advent of drug therapies that 
specifically interfere with neuronal serotonin reuptake, there has been little investigation 
of the relationship of this system to the thyroid system.21
To date, seven structurally and pharmacologically distinct receptor subtypes (5-HT1-7) 
have been identified, and these subfamilies have been further re-assigned into 14 
subtypes.35 All 5-HT receptor subtypes are G-protein-coupled receptors, except for 5-HT3, 
which is a ligand-gated sodium ion channel. Among the subtypes, the 5-HT1A receptor is 
the most widely researched, due to its central role in the regulation of 5-HT 
neurotransmission and its involvement in the pathophysiology of the stress response, 
aggressive behavior, anxiety, depression, and schizophrenia.10,36-38 These receptors are 
distributed universally throughout the CNS. They are localized at high densities in the 
cerebral cortex, hippocampus, septum, and raphe nucleus, but are found in very low 
amounts in the striatum, substantia nigra, and the cerebellum. The 5-HT1A receptors in the 
raphe nuclei are present in the cell bodies and dendrites of 5-HT neurons, and hence are 
called somatodendritic autoreceptors. At presynaptic sites, they act as reuptake 
modulators of synaptic 5-HT, causing a decreased release of 5-HT into the terminal fields. 
5-HT1A receptors are also located postsynaptically in the cortical and limbic area.
84. Thyroid-Serotonin interaction in neuropsychiatric disorders
Clinical and neuroanatomical studies have suggested that there is an interaction 
between thyroid hormones and serotonin in the pathophysiology of various 
neuropsychiatric disorders. It has been established that serotonin plays a major role in 
mood modulation. Serotonin pathways begin in the brainstem and extend through the 
midbrain into the limbic system and cortex, modulating the activity of many of the brain 
regions involved in emotion and memory. Thyroid hormones play an important role in the 
production of key enzymes for the synthesis of neurotransmitters, including serotonin, 
norepinephrine, and dopamine.39 From the few neuro-endocrine challenge studies which 
have been conducted in humans with thyroid dysfunction, there is some evidence that 
hypothyroid status is associated with reduced 5-HT responsiveness.21 Furthermore, this 
appears to be reversible with thyroid replacement therapy.40 Results from animal studies 
have provided strong evidence that thyroid status has a considerable impact on 
serotonergic neurotransmission in the adult brain. For example, experimentally induced 
hypothyroid status results in an increase in 5-HT turnover in the brainstem.41,42 This 
increased 5-HT turnover in hypothyroid status may lead to an increase in raphe 5-HT1A
autoreceptor activity and a decrease in cortical 5-HT concentrations. One animal study 
has also revealed that 5-HT content is decreased in the cerebral hemisphere and 
mesodiencephalon in hypothyroidism.39
5. Positron emission tomography
PET is a non-invasive imaging technique that provides biological and physiological 
information about living systems. The PET system detects pairs of gamma rays emitted 
indirectly by a positron-emitting radionuclide (radiotracer), which is introduced into the 
body attached to a biologically active molecule. Three-dimensional images of tracer 
concentration within the body are then constructed by computer analysis. A major 
advantage of PET is its high sensitivity (10-9-10-12 M), which allows for detection of the 
9interactions between radioligands and their protein targets. This sensitivity is many orders 
of magnitude greater than the sensitivity achieved with magnetic resonance imaging 
(MRI) (approx. 10-4 M), or computed tomography (approx. 10-3 M).43,44
Its uses in brain imaging have spanned both research interests and clinical 
applications. Specific psychiatric disorders in which PET studies may influence patient 
management include mood and anxiety disorders, attention deficit disorder, schizophrenia, 
and obsessive compulsive disorder.45 18F-fluoro-2-deoxyglucose, a tracer for glucose 
metabolism, has been most widely investigated for use in clinical PET brain imaging. 
However, in studies of psychiatric disorders, there has been an increasing demand for 
more specific radiotracers that bind to the receptors of various neurotransmitters—such as 
serotonin, dopamine, and opiate—and may play an important role in the study of 
psychiatric disorders.46,47
6. Radioligands for imaging 5-HT1A receptors
In recent decades, extensive investigations have been undertaken to develop an 
effective PET tracer for imaging 5-HT1A receptors, but only 3 radioligands are currently 
being used in human subjects: [11C]N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-2-
pyridinylcyclohexanecarboxamide ([11C]WAY-100635), [18F]trans-4-fluoro-N-2-[4-(2-
methoxyphenyl)piperazin-1-yl]ethyl]-N-(2-pyridyl)cyclohexanecarboxamide 
([18F]FCWAY), and 4-[18F]-fluoranyl-N-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-N-
pyridin-2-ylbenzamide ([18F]MPPF) (Fig. 1).
However, there are several obstacles to the widespread use of these radioligands. 
The production of [11C]WAY-100635 requires an expensive on-site cyclotron because its 
half-life is only 20 min. [18F]MPPF overcomes this issue, but it is a substrate for P-
glycoprotein in rodents and humans and thus shows poor brain penetration.48
[18F]FCWAY has a high affinity and selectivity for the target,49 but suffers from marked 
defluorination, which increases the skull uptake and hampers the exact quantification of 
5-HT1A receptors.50
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To circumvent the problem of the defluorination of radioligands, the Mukherjee 
group developed [18F]Mefway.51 [18F]Mefway is an [18F]-labeled analogue of [11C]WAY-
100635 that shows improved metabolic stability in vivo by extending the carbon bond on 
the cyclohexyl ring of [18F]FCWAY. In previous studies, [18F]Mefway has shown high 
affinity for 5-HT1A receptors, an excellent target-to-reference ratio, 5-HT1A-specific 
images without defluorination in the rhesus monkey, and favorable drug-like properties 
for 5-HT1A receptors.
17,51,52
Figure 1. PET radioligands for imaging 5-HT1A receptors.
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7. Purpose of the research
The purpose of this study was to evaluate the effect of hypothyroidism on 5-HT1A
receptors in the rat brain, specifically in the hippocampus and septum, using 
hypothyroidism animal models and [18F]Mefway PET imaging.
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II. MATERIALS AND METHODS
1. Synthesis of [18F]Mefway
[18F]Mefway was synthesized by a nucleophilic substitution reaction of a p-tosylated 
precursor, as has been previously described.53 The specific activity after completion of 
synthesis as assessed by high-performance liquid chromatography was higher than 90 
GBq/μmol, and the radiochemical purity exceeded 99%. 
2. Experimental animal models
Surgically thyroidectomized 6-week-old male Sprague-Dawley rats (n = 5) (Central 
Lab. Animal Inc., Seoul, Korea), initially weighing 175-200 g, were used in this 
experiment and were assigned to the disease animal group. The thyroidectomized rats 
were housed for two weeks, with four per cage, at uniform temperatures, with alternating 
12 hour cycles of light and dark. They received a rat chow diet and had free access to 0.5% 
CaCl2 drinking water.
Sham-operated male Sprague-Dawley rats of the same age (n = 5) were assigned to 
the control group. The sham-operated rats were also housed for two weeks, with four per 
cage, at uniform temperatures, with alternating 12 hour cycles of light and dark. Sham 
rats received rat chow and had free access to normal drinking water.
To verify the hypothyroid status of the thyroidectomized rats, T3, T4, and TSH 
levels were determined using the RTHYMAG-30K Milliplex MAP Rat Thyroid Magnetic 
Bead Panel (Millipore Corporation, Billerica, MA, USA). The detailed procedure was as 
follows: The plate was wet with a 150 μL wash buffer for 10 min, and the buffer was then 
decanted. Next, 25 μL of standards or samples, 25 μL of beads, and 25 μL of assay buffer 
were added to the plate, and the plate was incubated overnight at 4°C. The beads were 
then washed three times, after which 50 μL of biotinylated detection antibody cocktail 
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was added, and the plate was incubated at room temperature for one hour. Subsequently, 
50 μL of streptavidin-phycoerythrin was added and the plate was incubated at room 
temperature for a further 30 min. Lastly, the beads were washed three times, 150 μL of 
sheath fluid was added, and the plate was then read on a Luminex® plate-reader 
(Luminex Corporation, Austin, TX, USA). Analyses of thyroid hormones were performed 
at KOMABIOTECH Inc. (Seoul, Korea).
3. PET data acquisition
PET scanning was performed with a Siemens Inveon small animal PET scanner 
(Siemens Medical Solutions, Erlangen, Germany). This scanner has a peak absolute 
system sensitivity of ≥ 10% in the 250-750 KeV energy window, an axial field of view of 
12 cm, a 1.4 mm full width at half maximum spatial resolution at the center of the field of 
view, and a transaxial field of view of 10 cm. 
Anesthesia was induced with 2.5% isoflurane and was maintained during the PET 
scan with 1.5% isoflurane for 3 h (Fig. 2). After cannulation in a tail vein, rats were 
positioned in the center of a gantry. Then, to suppress the in vivo defluorination, rats were 
pretreated with fluconazole (60 mg/kg, One Flu injection, JW Pharmaceutical Co., Ltd., 
Seoul, Korea).52 Tracer accumulation in the brain was investigated by dynamic PET 
scanning over a period of 120 min after injection of 8.6–11.1 MBq of [18F]Mefway. 
Paired Sprague-Dawley rats that received sham surgery were used as controls. Thereafter 
attenuation corrections were performed using data from a 10 min transmission scan with a 
57Co point source.
PET data were reconstructed in user-defined time frames (10 sec × 6 frames, 30 sec 
× 8 frames, 300 sec × 5 frames, 1800 sec × 3 frames) with a voxel size of 0.86 × 0.86 × 
0.80 mm3, using a 2-dimensional ordered-subset expectation maximization algorithm (4 
iterations and 16 subsets).
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Figure 2. Temporal course of the dynamic PET study. Rats were pre-treated with 
fluconazole to prevent defluorination of the radiotracer. Dynamic brain PET scanning 
was performed after administration of [18F]Mefway, over a period of 120 min.
4. Image processing
The procedure used for the template construction was based on work by Casteels et 
al.,54,55 but revised to obtain symmetrical templates.56 The procedure for the construction 
of functional templates was divided into three steps (Fig. 3). First, a representative image 
of each set of tracers was selected as a “standard” for that specific tracer. Next, each of 
the individual scans was normalized into the space of the representative scan. This 
within-modality affine registration was achieved by minimizing the sum of squares 
differences between the image to be normalized and the reference image. Secondly, a 
symmetrical voxel-wise averaged template was obtained from the previously aligned 
images. To this end, a left-right flipped duplicate of the previously obtained average 
image was created, and this was normalized into the original average template. Thirdly, a 
cross-modality registration was performed between the symmetrical averaged image and 
the reference MRI that was in the same space as the PET templates. A T2-weighted MRI 
template was used for spatial normalization and co-registration.57 This procedure was 
performed using a rigid-body transformation based on the normalized mutual information 
maximization algorithm. Thereafter, the transformation matrix obtained in the co-
registration was applied to all of the images used in the construction of the template, for 
further use in the study.
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Figure 3. Schematic representation of the construction pathway for functional PET
atlases. MR, magnetic resonance.
5. Kinetic modeling and parametric mapping
Making use of the stereotactic rat brain atlas, we defined a volume of interest (VOI) 
map on the MRI template that represented the major cortical and subcortical structures of 
the rat brain. Each region was primarily defined on coronal slices, with sagittal and axial 
slices used to confirm regional boundaries. VOIs were defined for the rat brain 
hippocampus, septum, and cerebellum. After VOIs were superimposed on the normalized 
PET image (Fig. 4), time-activity curves (TACs) were extracted from each VOI and
presented in units of standardized uptake value to normalize the differences in rat weight 
and administered dose.57
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Figure 4. Predefined volumes of interest for time-activity curves and quantitative 
analyses. PET images were spatially co-registered to the T2-weighted magnetic 
resonance imaging template. Predefined volumes of interest of the septum, hippocampus, 
and cerebellum were overlaid on the time-averaged dynamic PET data (20–60 min) for 
time-activity curves and for quantitative analyses. H, hippocampus; S, septum; Cb,
cerebellum.
17
For quantitative analysis, we used kinetic modeling and generated parametric images 
of [18F]Mefway PET. Non-displaceable binding potential (BPND) was used to evaluate 
receptor density. The cerebellum was used as the reference region because it contains 
very few 5-HT1A receptors in adult rats.58 Individual binding value estimations in the 
hippocampus and septum were computed based on a multilinear reference tissue model, 
and the estimated BPND values were calculated.59
Kinetic analyses and voxel-based BPND mapping were performed using PMOD 3.3 
(PMOD Technologies Ltd., Adliswil, Switzerland). Parametric BPND maps were 
smoothed with a Gaussian filter of 1.2 mm full width at half maximum.
6. Comparison of regional [18F]Mefway BPND
We determined the [18F]Mefway BPND of predefined VOIs, including the 
hippocampus, septum, and cerebellum, in thyroidectomized as well as control rats. Using 
spatially normalized BPND maps and the VOIs, regional BPND was determined in both the 
animal disease models and controls. Regional BPND in the thyroidectomized rats was 
compared with that in controls.
7. Statistical analysis
All data were presented as mean ± standard deviation or standard errors of the mean. 
The differences in BPND were analyzed using the Mann-Whitney U test. All statistical 
analyses were performed with GraphPad Prism version 5.04 (GraphPad Software, Inc., 
San Diego, CA, USA).
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III. RESULTS
1. Validation of the hypothyroid animal model
T3 and T4 levels in the thyroidectomized rats were 7.9 ± 0.1 ng/ml and 235.6 ± 17.2 
ng/ml, respectively, and were significantly lower than those in controls (12.5 ± 0.8 ng/ml, 
496.4 ± 48.0 ng/ml, respectively; both p < 0.01; Table 1). The thyroidectomized group 
showed significantly higher levels of serum TSH than did the control group (21.1 ± 1.7 
ng/ml vs. 1.9 ± 0.1 ng/ml; p < 0.01). Finally, hypothyroid status was confirmed based on 
the lower T3 and T4 levels and higher TSH levels in thyroidectomized rats as compared 
with those in the control rats.
Table 1. Results of thyroid function tests1 Hypothyroidism was verified in the 
thyroidectomized rats by low serum T3 and T4 values and high TSH values
Group TSH (ng/ml) T3 (ng/ml) T4 (ng/ml)
Thyroidectomized 21.1 ± 1.7 7.9 ± 0.1 235.6 ± 17.2
Control 1.9 ± 0.1 12.5 ± 0.8 496.4 ± 48.0
1Values are expressed as mean ± standard deviation (n = 5 for each group).
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2. Comparison of regional [18F]Mefway uptake
Dynamic PET images were averaged between 20 and 60 min time-periods. 
Representative PET images showed globally increased [18F]Mefway in the whole brain, 
including the hippocampus and septum (Fig. 5). 
Time-activity curves revealed that the thyroidectomized rats showed a significant 
increase in [18F]Mefway uptake in the hippocampus and septum, compared to the sham-
surgery group. The degrees of [18F]Mefway uptake in these two regions were 25–52% 
higher than those of the control group (Fig. 6). 
Figure 5. Representative [18F]Mefway PET images. PET images were averaged 
between 20 and 60 min. When compared to the control group (A), both septal and 
hippocampal uptakes were significantly higher in the thyroidectomized group (B).
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Figure 6. Time-activity curves of [18F]Mefway uptake in specific regions of the brain.
The degree of regional radiotracer uptake was expressed as a standardized uptake value.
When compared to the control group (A), [18F]Mefway uptake in the hippocampus and 
septum was 25–52% higher in the thyroidectomized group (B). In contrast, cerebellar 
uptake was similar in both groups, characterized by a rapid washout followed by a plateau 
at a low concentration in the later phase.
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3. Changes of [18F]Mefway BPND in hypothyroidism
Using predefined VOIs, the [18F]Mefway BPND of each brain region of the rats in the 
hypothyroidism model group was compared with that of the rats in the control group. As 
shown in Fig. 7, the [18F]Mefway BPND of the hippocampus was increased in the 
thyroidectomized group (3.4 ± 0.4) as compared to the control group (2.7 ± 0.4; p < 0.01). 
In the septum, the [18F]Mefway BPND of the thyroidectomized rats demonstrated a 
significantly higher uptake than that seen in the controls (3.0 ± 0.4 vs. 2.5 ± 0.4; p < 0.01). 
Parametric images of [18F]Mefway BPND were generated using a multilinear 
reference tissue model. In the hypothyroidism model group, BPND was significantly 
increased in the hippocampus and septum, as compared to the control group (Fig. 8).
Figure 7. Comparison of the [18F]Mefway BPND in different brain regions. The 
thyroidectomized group showed significantly higher BPND in both the hippocampus (A) 
and the septum (B) (*p < 0.01) compared with that seen in the controls. Values are 
expressed as mean ± the standard error of the mean.
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Figure 8. Representative BPND parametric map. Compared to the control group (A), 
the thyroidectomized group (B) shows higher BPND values in the hippocampus and 
septum, which is consistent with the result of the volume-of-interest-based analysis.
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IV. DISCUSSION
This was the first non-invasive functional imaging study of the effect of 
hypothyroidism on 5-HT1A receptors in the rat brain, specifically in the limbic system. In 
thyroidectomized rats, both [18F]Mefway uptake and BPND were significantly higher than 
in the sham-operated rats. The results of the present study may facilitate understanding of 
the pathophysiology of neuropsychiatric disorders in terms of HPT axis dysfunction, and 
may show the translational possibility of using [18F]Mefway to image 5-HT1A receptors in 
patients with neuropsychiatric disorders. 
1. Measurement of regional [18F]Mefway uptake
The 5-HT system is known to regulate various brain functions, such as mood, 
appetite, sleep, and cognition. Two major pathways have been described for the 5-HT 
projections from the dorsal raphe nucleus to the forebrain.60 Although there is extensive 
overlap between raphe projections, the dorsal raphe projects to the frontal cortex and 
striatum, while the median raphe innervates the hippocampus and the septum. 5-HT1A
receptors, key players in the CNS 5-HT system, are heterogeneously distributed 
throughout the rat brain. The dorsal raphe nucleus and limbic system have abundant 5-
HT1A receptors, while these receptors are scarce in the cerebellum and brainstem. In the 
presynapses of the raphe nucleus, they act as autoreceptors that modulate the reuptake of 
synaptic 5-HT, causing a decrease in the release of 5-HT into the terminal fields. 5-HT1A
receptors are also located postsynaptically in the cortical and limbic area.61
In the present study, the hippocampus and septum were selected as regions of 
interest because they were known to comprise major afferent pathways of 5-HT 
neurotransmission within the limbic system, which supports a variety of functions 
including emotion, behavior, motivation, long-term memory, and olfaction. The high 
receptor density in these regions indicated that the 5-HT1A receptor played an important 
role in mood, behavior modulation, and cognitive functions. For example, several MRI 
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studies have revealed a lower hippocampal volume in patients suffering from 
depression.62 A morphometric analysis has also shown a decreased volume of septal 
nuclei in schizophrenia and affective disorders.63
In our study, the time-activity curves for [18F]Mefway in the cerebellum were 
characterized by rapid washout, followed by low radioactivity concentrations over 2 h
(Fig. 6). This cerebellar uptake pattern is similar for other 5-HT1A radioligands, resulting 
in low counting statistics in the cerebellum at later stages. Low cerebellar uptake is 
largely due to the scanty amount of 5-HT1A. However, unlike the metabolites of 
[11C]WAY-100635, the metabolites of [18F]Mefway do not cross the blood-brain barrier 
and therefore do not contribute to an increase in nonspecific radioactivity in the brain, 
thereby facilitating biomedical modeling of PET data. One potential cause of the low 
cerebellar uptake could have been the presence of a P-glycoprotein transporter, but this 
requires further investigation in the future. 
In this study, quantitative analysis was not performed for the raphe nucleus, which 
also has abundant 5-HT1A receptors. The raphe nucleus has already been a region of 
interest in the field of 5-HT receptor studies because presynaptic 5-HT receptors in this 
region function as a point of control for activity in 5-HT neurons. Furthermore, one 
animal study has indicated that it is feasible to delineate the raphe nucleus in rat brain 
PET images.17 As shown in Fig. 6, there was a distinct area of increased radiotracer 
uptake against the background of scanty uptake in the brainstem that probably 
corresponded to the raphe nucleus; however, reliable segmentation of radioactivity in the 
raphe nucleus seems to be difficult without accurate anatomic information, and becomes 
more cumbersome when the receptor density changes in the region. Manual segmentation 
of raphe nucleus radioactivity is somewhat arbitrary and is susceptible to both 
overestimation and underestimation, specifically in animal models of disease. For this 
reason, the raphe nucleus was not included in the quantitative analysis.
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2. Mechanism of increased [18F]Mefway uptake in the brain after thyroidectomy
The density of 5-HT1A receptors has been studied most in experimentally induced 
hypothyroid animals. Studies of the density of 5-HT1A (postsynaptic) receptors outside 
the brainstem, however, have yielded contradictory results. An increase in cortical and 
hippocampal 5-HT1A receptors was observed by Tejani-Butt et al.,64 but not by Hong et 
al.65 and Kulikov et al.,66 who found no significant differences as compared to euthyroid 
adult rodents. Furthermore, clinical studies of patients with major depressive disorder 
have consistently detected a decrease in 5-HT1A receptor binding in the raphe nucleus and 
limbic and cortical regions.67-69
In this study, BPND was used as a measure of receptor density, and there was greater 
binding in the limbic regions of thyroidectomized animals relative to those of the control 
animals. One mechanism suggested for this increased radioligand uptake is the 
upregulation of postsynaptic 5-HT1A receptors as an early response to a local decrease in 
5-HT in the synaptic region. 
Previous studies have demonstrated that hypothyroidism alters the function of the 
hippocampus, resulting in cognitive impairment, anxiety, and depressive symptoms in 
rodent models and humans.70,71 It has also been reported that reduced neurogenesis is 
responsible for neurocognitive problems, anxiety, depression,72 and neurodegenerative 
diseases.73 Recently, the subgranular zone of the hippocampal dentate gyrus and the 
subventricular zone have been considered to be the two main places where neurogenesis 
occurs in the adult mammalian brain.74 Thyroid hormone, specifically T3, was reported to 
regulate cell proliferation and neural stem cell commitment toward the neuroblast in both 
the rodent subgranular zone and subventricular zone.75,76 In one study, hypothyroidism in 
adult rats induced a decrease of proliferation by 30% in the adult subgranular zones that 
was restored by thyroid hormone replacement.77 Thus, it is suggested that 
neuropsychiatric disorders associated with hypothyroidism may be related to reduced 
hippocampal neurogenesis.
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Studies have supported changes in the brains of hypothyroid adult rats as follows: an 
increase in 5-hydroxyindoleacetic acid, the main 5-HT metabolite, in the brainstem;42,78,79
a reduced 5-HT concentration in the cortex;39 and a decreased concentration of serotonin 
precursor (5-hydroxytryptophan) throughout the brain.80 On the basis that there is 
increased 5-HT turnover in the brainstem, and decreased levels of 5-HT and its precursors 
in other brain regions, it can be concluded that hypothyroidism causes a decrease in 5-HT 
release in the cortical projection area by increasing 5-HT turnover in the brainstem and 
consequently activating the raphe 5-HT1A autoreceptors. 
When there is a prolonged lack of stimulation due to reduced amounts of 
neurotransmitter, there is often an increase in the number of cell receptors, hence the 
postsynaptic neurons become hypersensitive. We hypothesized that this hypersensitive 
response to a decreased 5-HT concentration may be responsible for the increased 
[18F]Mefway uptake in the limbic region after thyroidectomy. Such a result would be 
consistent with a 5-HT receptor study by Tejani-Butt et al.64 In addition, if a decrease in 
5-HT concentration persists for a long time, this may eventually result in the 
downregulation of 5-HT1A receptors in the cortex and limbic system, causing a reduced 
radiotracer uptake in the corresponding regions. The temporal change in the postsynaptic 
cellular response to decreased 5-HT concentration may account for the contradictory 
results from previous and present studies. However, this assumption requires further 
investigation and validation. If the dissociation constant is the same in the experimental 
and control groups, the increase in the binding potential can be attributed to an increase in 
the available 5-HT1A receptor on the plasma membrane. When the 5-HT concentration is 
lowered in the synapse, the 5-HT1A receptor is initially upregulated in response to it, but it 
is expected to be down-regulated later. The change in the later time should be further 
validated. 
In the present study, we did not further confirm the reversal of increased 5-HT1A
receptor density produced by the thyroidectomy via thyroid hormone replacement. It was 
because the rest-retest reliability of [18F]Mefway PET has not been validated in the 
rodents; that is, PET results from different time points in the same animal may give 
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different results. And we did not evaluate the changes in the 5-HT1A transporter, either. It 
is well known that regulation of the transporter is also essential in the modulation of 
neurotransmission at the synapse. A few animal studies have reported that the 5-HT1A
transporter density remained unchanged in hypothyroidism based on the Wistar rat 
model,66,81 but it is possible that a difference in species may yield different results, as 
found in the 5-HT1A receptor studies.
3. The advantages of [18F]Mefway
With regard to the applicability of these findings to clinical research, [18F]Mefway 
has several advantages over the currently available radioligands for 5-HT1A receptor 
imaging, that is, [11C]WAY-100635, [18F]FCWAY, and [18F]MPPF. First of all, 
[18F]Mefway has a practical advantage in its use of 18F. [11C]-radioligands have limited 
utility due to the short half-life of 11C (t1/2 = 20 min). Thereby, PET facilities that lack a 
cyclotron have difficulty in acquiring such radioligands from distant cyclotron centers. 
For accurate quantification of hippocampal 5-HT1A levels, longer scan times (> 2 h) are 
required because the equilibrium time of the radioligand to the 5-HT1A receptors appears 
to exceed 2 h, thus further limiting the utility of [11C]-radioligands. 
Secondly, [18F]Mefway circumvents the defluorination issue that is the main barrier 
for the clinical application of [18F]FCWAY. Defluorination hampers the exact 
quantification of receptor density due to a spillover effect in which radioactivity in the 
skull can also be detected in nearby brain regions, such as the cortex. Besides 
defluorination, another practical drawback of [18F]FCWAY is that it is difficult to 
synthesize due to the low yield of 4-fluorocyclohexane carboxilic acid. A radioprobe and 
its precursor must have a sufficient and reproducible synthetic yield for use in PET 
experiments. 
Thirdly, the metabolites of [18F]Mefway do not cross the blood-brain barrier. The 
main advantage of [11C]WAY-100635 is its high target-to-background ratio, but its rapid 
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metabolism in plasma–with consequent crossing of the blood-brain barrier into the brain–
makes quantification more challenging and BPND estimates unreliable when the 
cerebellum is used as a reference tissue.82 In contrast, the metabolites of [18F]Mefway do 
not re-enter the brain, while showing comparable specific binding to the receptors.
Finally, [18F]Mefway PET can serve as a useful tool in animal research, making it 
possible to reduce the number of smaller animals required in longitudinal studies. In 
special situations, such as unilateral lesion studies, the reproducibility of data from these 
imaging studies may actually be superior to that obtained from traditional invasive 
techniques, because each animal serves as its own control. [18F]Mefway PET provides a 
bridge from animal research to human research and clinical applications.
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V. CONCLUSION
In the present study, we investigated [18F]Mefway uptake in the hippocampus and 
septum of experimental animal models of hypothyroidism, and VOI-based and voxel-
wise analyses showed concordant differences.
Effect of hypothyroidism on 5-HT1A receptors in the rat brain
A. The thyroid hormone assay verified the hypothyroid status of the 
thyroidectomized rats.
B. TACs showed that [18F]Mefway uptake in the hippocampus and septum of the 
thyroidectomized rats was 25–52% higher than the uptake in the sham-operated 
rats.
C. VOI and voxel-based analyses also showed a significant increase in the regional 
brain uptake in the hypothyroidism group, as compared with the control group. 
Quantitative analyses using VOI templates and a parametric map of BPND
A. [18F]Mefway-specific brain templates were constructed by spatial co-registration 
of PET data to T2-weighted MRI templates for the Sprague-Dawley rat brain.
B. Both VOI and voxel-wise analyses showed enhanced brain uptake in the 
thyroidectomized group, as compared to the sham-surgery group. 
These results suggest that hypothyroidism increases the density of postsynaptic 5-HT1A
receptors in the rat brain.
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ABSTRACT (IN KOREAN)
[18F]Mefway 양전자방출단층촬영술로 측정한
갑상선기능저하증이 쥐 뇌의 세로토닌 1A 수용체에 미치는 영향
<지도교수 유영훈>
연세대학교 대학원 의학과
이 재 훈
이 연구는 동물 질병 모델 및 4-(trans-[18F]fluoranylmethyl)-N-[2-[4-(2-
methoxyphenyl)piperazin-1-yl]ethyl]-N-pyridin-2-ylcyclohexane-1-carboxamide 
([18F]Mefway) 양전자방출단층촬영술(PET)을 사용하여 갑상선기능저하증이
뇌의 세로토닌 1A 수용체에 미치는 영향을 연구하였다.
갑상선절제술을 받은 Sprague-Dawley 수컷 쥐 5마리를 갑상선기능저하증
집단에 배정하였고, 모의 수술(sham operation)을 받은 Sprague-Dawley 수컷 쥐
5마리를 대조군으로 설정하였다. 갑상선기능저하 상태는 갑상선 기능 검사로
확인하였다. 산소에 2%의 아이소플루레인을 혼합하여 마취를 시킨 후, 
[18F]Mefway의 탈불소화를 방지하기 위하여, 1시간 동안 플루코나졸을
투여하였다. 그 다음 8.6–11.1 MBq의 [18F]Mefway를 1 ml/min 속도로 투여한 후, 
PET 영상을 120분간 연속적으로 획득하였다. PET 영상은 2차원 정칙화된
기댓값 최대화 알고리즘(ordered subsets expectation maximization algorithm)을
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이용하여 재구성하였다. 
모든 PET 영상은 T2 강조 자기공명영상 틀(template)에 공간정규화 한 후
사전 정의된 관심영역 틀을 이용하여 해마, 사이막(septum), 소뇌의
시간방사능곡선을 추출하였다. 해마와 사이막의 수용체 결합능(non-displaceable 
binding potential)은 소뇌를 참조조직으로 삼아 다중선형 참조조직
모형(multilinear reference tissue model)을 통하여 계산하였고 리간드-특정
모수지도(parametric map)를 작성하였다.
시간방사능곡선에서 갑상선기능저하증 집단의 해마와 사이막 섭취는
대조군보다 25-52% 더 많았고 이 부위의 결합능은 갑상선절제술을 받은
쥐에서 대조군에 비하여 30% 가량 더 높았다.
결론적으로, 갑상선기능저하증은 해마와 사이막의 시냅스후 세로토닌 1A 
수용체 밀도를 증가시켰다. 이는 갑상선기능저하증으로 인해 시냅스의
세로토닌 농도가 감소하고 이에 따른 초기 반응으로써 시냅스후 세로토닌 1A 
수용체가 상향조절 되었기 때문일 것이다.
핵심되는 말: [18F]Mefway, 갑상선기능저하증, 양전자방출단층촬영술, 세로토닌
1A 수용체, 갑상선
